Science-First Longevity Summit & Dinner

A new wave of science is transforming aging from an abstract concept into something we can measure, track, and ultimately influence. Researchers like Morgan Levine and Daniel Belsky have demonstrated that biological age can be quantitatively assessed, laying the foundation for a more precise understanding of aging. At the same time, innovators including Tony Wyss-Coray, Irina Conboy, and Kiana Aran are pioneering interventions that point toward actionable ways to modify aging processes, particularly through blood-based mechanisms.
Expanding beyond these approaches, scientists such as Paul Robbins, Anthony Molina, and Marco Demaria are advancing additional therapeutic pathways aimed at slowing or reversing key drivers of aging biology. On the clinical front, physician Robert Huizenga will share how longevity science has already translated into improved patient outcomes over the past decade. Complementing this, Raiany Romanni-Klein will provide insight into the global market landscape, drawing from two years of focused research on the commercial potential of these innovations.

No one in this room is selling you anything.
Every speaker is a working scientist: no pitches, no commercial agenda.
You’ll leave with the scientific literacy to evaluate any longevity company that approaches you.
This isn’t entertainment. It’s competitive intelligence.
Attendance is capped at 200 and curated by invitation.
This is not a conference you sign up for.
It’s a private briefing you’re selected to attend.
The timing is intentional, held one day before the Bay Area Aging Meeting at the Buck Institute, when the most serious players are already in the region.